Startseite Kongressberichte & Archiv 63rd ASH Annual Meeting and Exposition In-Person/Virtual CML Progress with response prediction and TKI discontinuation

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Progress with response prediction and TKI discontinuation

631

Koji Sasaki, Elias J. Jabbour, Ghayas C. Issa, et al.

Just as effective as standard-dose dasatinib is low-dose dasatinib, which has fewer intolerances. This results in a favorable outcome.

 

632

Xiaoshuai Zhang, Xiaojun Huang, Robert Peter Gale and Qian Jiang.

The predictive score for FFS described by the study authors identifies people with newly diagnosed chronic CML with initially imatinib with different probabilities of success. This should enable doctors to select the best TKI therapy strategy in this setting.

 
633 ASH denotes this abstract as clinically relevant

Francois-Xavier Mahon, Johan Richter, Andreas Hochhau, et al.

This final analysis of the largest TFR study confirms the MRecFS and MRecTFS rates from the interim analysis. However, late molecular relapse (15% between 6 and 36 months) was observed. Nevertheless, almost half (46%) were still in MRecTFS at 3 years.

 

634

Katia B Pagnano, Chung Hoow Kok, Michael J. Mauro, et al.

Older CML patients (> 75 years) with COVID-19 have a higher mortality rate. Likewise for CML / COVID-19 patients with cardiovascular or pulmonary comorbidities and from countries with low and middle income. There were also more deaths in patients in advanced stages and in those without MMR.

 

635

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, et al.

An additional year of NIL-CONS for CML-CP who achieved a sustained DMR after switching from IM after 2 years with NIL does not bring any significant incremental advantage in terms of TFR success. The efficacy of NIL (300 mg BID) in achieving MR in patients who were unable to achieve sustained DMR with 1st-line IM for ≥ 24 months was confirmed without any new safety signals.